MX390084B - Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. - Google Patents

Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.

Info

Publication number
MX390084B
MX390084B MX2018003893A MX2018003893A MX390084B MX 390084 B MX390084 B MX 390084B MX 2018003893 A MX2018003893 A MX 2018003893A MX 2018003893 A MX2018003893 A MX 2018003893A MX 390084 B MX390084 B MX 390084B
Authority
MX
Mexico
Prior art keywords
cough
diaminopyrimidine
treatment
receptor modulators
methods
Prior art date
Application number
MX2018003893A
Other languages
English (en)
Other versions
MX2018003893A (es
Inventor
Anthony P Ford
Kathleen Sereda Glaub
Michael M Kitt
Steven Smith
Original Assignee
Afferent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afferent Pharmaceuticals Inc filed Critical Afferent Pharmaceuticals Inc
Publication of MX2018003893A publication Critical patent/MX2018003893A/es
Publication of MX390084B publication Critical patent/MX390084B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Metodos de tratamiento de la tos, tos cronica y deseo de toser asociados con enfermedades respiratorias, con un antagonista del receptor P2X3 y/o P2X2/3, los métodos comprendiendo administrarle a un sujeto que lo necesite una cantidad eficaz de 5 un compuesto de la formula (I): ver fórmula (I), o una sal farmaceuticamente aceptable del mismo, en donde R1 y R2 son como se define en la presente.
MX2018003893A 2015-09-29 2016-09-23 Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. MX390084B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562234584P 2015-09-29 2015-09-29
US201662336381P 2016-05-13 2016-05-13
PCT/US2016/053223 WO2017058645A1 (en) 2015-09-29 2016-09-23 Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough

Publications (2)

Publication Number Publication Date
MX2018003893A MX2018003893A (es) 2018-06-22
MX390084B true MX390084B (es) 2025-03-20

Family

ID=58424436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003893A MX390084B (es) 2015-09-29 2016-09-23 Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.

Country Status (23)

Country Link
US (3) US11260056B2 (es)
EP (2) EP3355889B1 (es)
JP (1) JP6877441B2 (es)
KR (2) KR20260022473A (es)
AU (1) AU2016330466B2 (es)
CA (1) CA2998742C (es)
CY (2) CY1125963T1 (es)
DK (1) DK3355889T3 (es)
ES (1) ES2942711T3 (es)
FI (2) FI3355889T3 (es)
FR (1) FR24C1010I2 (es)
HR (1) HRP20230445T1 (es)
HU (2) HUE061764T2 (es)
LT (2) LT3355889T (es)
LU (1) LUC00332I2 (es)
MX (1) MX390084B (es)
NL (1) NL301260I2 (es)
NO (1) NO2024009I1 (es)
PL (1) PL3355889T3 (es)
PT (1) PT3355889T (es)
RS (1) RS64155B1 (es)
SI (1) SI3355889T1 (es)
WO (1) WO2017058645A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021120039A (ru) * 2016-12-20 2021-08-03 Эфферент Фармасьютикалз, Инк. Кристаллические соли и полиморфы антагониста p2x3
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
JP2021523919A (ja) * 2018-05-15 2021-09-09 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 神経線維感作に関連する疾患を治療するための１，３−チアゾール−２−イル置換ベンズアミド
PL3862000T3 (pl) * 2018-10-05 2024-03-18 Shionogi & Co., Ltd Lek na przewlekły kaszel
WO2020174283A1 (en) 2019-02-25 2020-09-03 Bellus Health Cough Inc. Treatment with p2x3 modulators
US20220211703A1 (en) * 2019-04-30 2022-07-07 Beijing Tide Pharmaceutical Co., Ltd. Method for treating cough by using diaminopyrimidine compound
KR102921974B1 (ko) 2019-05-31 2026-02-05 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 아미노 퀴나졸린 유도체
KR102923602B1 (ko) 2019-05-31 2026-02-06 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 피리도피리미딘 유도체
MX2022002941A (es) 2019-09-19 2022-04-06 Shionogi & Co Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
WO2022112491A1 (en) 2020-11-27 2022-06-02 Chiesi Farmaceutici S.P.A. (aza)quinoline 4-amines derivatives as p2x3 inhibitors
EP4251273B1 (en) 2020-11-27 2025-03-12 Chiesi Farmaceutici S.p.A. Phthalazine derivatives as p2x3 inhibitors
CA3196333A1 (en) 2020-11-27 2022-06-02 Claudio FIORELLI Amino quinazoline derivatives as p2x3 inhibitors
CN116396285A (zh) * 2022-01-04 2023-07-07 上海华汇拓医药科技有限公司 氘代四氢呋喃类化合物制备及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1725540T5 (da) 2004-03-05 2012-10-22 Hoffmann La Roche Diaminopyrimidiner som p2x3- og p2x2/3-antagonister
JP2008507368A (ja) 2004-07-22 2008-03-13 デュスカ サイエンティフィック カンパニー 肺疾患を診断、モニタリングおよび治療するための方法
ES2562056T3 (es) 2005-09-01 2016-03-02 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores P2X3 y P2X2/3
CN101296907B (zh) 2005-09-01 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类
WO2007025898A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Process for synthesis of aryloxy diaminopyrimidines
CA2620034C (en) 2005-09-01 2013-10-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
EP2079713B1 (en) 2006-10-04 2014-04-16 F. Hoffmann-La Roche AG Process for synthesis of phenoxy diaminopyrimidine derivatives
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
JP6546592B2 (ja) 2013-08-23 2019-07-17 アファレント ファーマシューティカルズ インコーポレイテッド 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター

Also Published As

Publication number Publication date
AU2016330466B2 (en) 2021-01-28
HRP20230445T1 (hr) 2023-07-21
CY2024005I2 (el) 2024-09-20
MX2018003893A (es) 2018-06-22
CY2024005I1 (el) 2024-09-20
JP2018529776A (ja) 2018-10-11
HUS2400004I1 (hu) 2024-04-28
US20180280388A1 (en) 2018-10-04
KR20260022473A (ko) 2026-02-19
NL301260I2 (nl) 2024-03-25
CY1125963T1 (el) 2024-09-20
LT3355889T (lt) 2023-05-10
LUC00332I2 (es) 2026-03-04
FIC20240006I1 (fi) 2024-03-13
EP3355889A1 (en) 2018-08-08
NO2024009I1 (no) 2024-03-06
FI3355889T3 (fi) 2023-05-15
ES2942711T3 (es) 2023-06-06
RS64155B1 (sr) 2023-05-31
CA2998742A1 (en) 2017-04-06
WO2017058645A1 (en) 2017-04-06
FR24C1010I1 (fr) 2024-05-24
KR20180054843A (ko) 2018-05-24
US11260056B2 (en) 2022-03-01
LTPA2024507I1 (es) 2024-04-10
EP3355889B1 (en) 2023-02-15
US20240285620A1 (en) 2024-08-29
AU2016330466A1 (en) 2018-03-29
DK3355889T3 (da) 2023-05-15
HUE061764T2 (hu) 2023-08-28
EP4215182A1 (en) 2023-07-26
EP3355889A4 (en) 2019-05-22
SI3355889T1 (sl) 2023-07-31
US20220143015A1 (en) 2022-05-12
CA2998742C (en) 2023-08-29
PT3355889T (pt) 2023-04-26
PL3355889T3 (pl) 2023-05-22
JP6877441B2 (ja) 2021-05-26
FR24C1010I2 (fr) 2024-12-13

Similar Documents

Publication Publication Date Title
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
PH12016500357A1 (en) Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
BR112015022197A2 (pt) tratamento de cataplexia
MX376164B (es) Composiciones y metodos para tratar el insomnio.
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
EA201591628A1 (ru) Дейтерированный палбоциклиб
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
PH12016502353A1 (en) Pharmaceutical composition
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX390051B (es) Antagonistas de ep4.
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
GEAP201814255A (en) P-substituted asymmetric ureas and medical uses thereof
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
TR201906539T4 (tr) Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.